AAV2-GDNF

DRUG4 trials

Sponsors

Askbio Inc., Askbio Inc., AskBio France, Brain Neurotherapy Bio, Inc.

Conditions

Multiple System AtrophyParkinson's DiseaseParkinson’s Disease

Phase 1

GDNF Gene Therapy for Parkinson's Disease

Active, not recruitingNCT04167540

Brain Neurotherapy Bio, Inc.Parkinson's Disease

Start: 2020-04-01End: 2027-06-30Updated: 2025-09-19

Phase 2

(ASK-PD5-CS201) A Phase 2, Randomized, Double-blind, Sham Surgery-controlled Study of the Efficacy and Safety of Intraputaminal AAV2-GDNF in the Treatment of Adults with Moderate Stage Parkinson’s Disease

RecruitingCTIS2023-506519-16-00

Askbio Inc.Parkinson’s Disease

Start: 2025-04-11Target: 55Updated: 2026-01-27

Open-Label, Multi Stage Study to Optimize the Intraputaminal Administration of AB-1005 Using a Prescriptive Infusion Algorithm (PIA)

Not yet recruitingCTIS2025-522441-21-00

Askbio Inc., AskBio FranceParkinson's Disease

Target: 12Updated: 2026-04-03

Phase 4

(ASK-PD0-CS002) Long-Term Safety and Efficacy Follow-up of AB-1005 Gene Transfer Study Participants with Parkinson’s Disease or Multiple System Atrophy

Not yet recruitingCTIS2025-522653-19-00

Askbio Inc., AskBio FranceMultiple System Atrophy, Parkinson's Disease

Target: 40Updated: 2025-12-22